Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis

Summary

Possible correlation of the effects of pharmacotherapy on the inhibition of the in-vivo generation of thrombin and on the prevention of thrombus extension in patients with deep vein thrombosis (DVT) could help to define patients at higher risk.

Patients with symptomatic deep vein thrombosis confirmed by phlebography were randomised to intravenous unfractionated heparin (UFH), or a subcutaneous low-molecular-weight heparin (reviparin) twice daily for one week, or a subcutaneous reviparin once daily for four weeks. The patients were treated with oral anticoagulants for at least 3 months. Main endpoints were regression of thrombus on phlebography on Day 21 and recurrent symptomatic venous thromboembolism up to 3 months. Coagulation parameters, markers of in-vivo thrombin generation, and TFPI-release were determined at randomisation, weeks 1 and 3.

Four hundred sixty six responders (reduction of at least 30 per cent in Marder score) and 419 non-responders (Marder score unchanged or changed less than ±30%) showed no significantly different baseline characteristics. The non-responder group had a higher median Marder score at baseline and after one and three weeks of treatment, and had significantly higher fibrinogen levels, TAT complexes and F1+2 values than responders. There were no significant differences in coagulation parameters between non-responders and patients with asymptomatic + symptomatic VTE with the exception of higher TAT complexes at baseline.

Significant differences in Marder score and coagulation parameters at baseline were found between responders and non-responders. Non-responders have a higher risk tosuffer recurrent VTE and may need intensified treatment.

Keywords

LMWH - acute DVT - thrombin generation - phlebographic response - rethrombosis

• References

• 1 Holm HA, Ly B, Handeland GF. et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low-molecular-weight heparin. Haemostasis 1986; 16 (Suppl. 02) (Suppl) 30-7.
• 2 Handeland GF, Abildgaard U, Holm HA. et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low-molecular-weight heparin. Eur J Clin Pharmacol 1990; 39: 107-12.
• 3 Bratt G, Aberg W, Johansson M, Tornebohm E. et al. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10.
• 4 Prandoni P, Vigo M, Cattelan AM, Ruol A. Treatment of deep vein thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990; 20 (Suppl. 01) (Suppl) 220-3.
• 5 A randomised trial of subcutaneous low-molecular-weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicentre study Thromb Haemost. 1991; 65: 251-6.
• 6 Hull RD, Raskob GE, Pineo GF, Green D. et al. Subcutaneous low-molecular-weight-heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
• 7 Prandoni P, Lensing AWA, Büller HR, Carta M. et al. Comparison of subcutaneous low-molecular-weight-heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
• 8 Simonneau G, Charbonnier B, Decousus H. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541-6.
• 9 Lindmarker P, Holmstom M, Granqvist S. et al. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
• 10 Fiessinger JN, Lopez-Fernandez M, Gatterer E. et al. Once-daily subcutaneous dalteparin, a low-molecular-weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
• 11 Luomanmaki K, Grankvist S, Hallert C, Jauro I. et al. A multicentre comparison of once-daily subcutaneous dalteparin (low-molecular-weight heparin) and continuous intravenous heparin in the treatment of deep venous thrombosis. J Intern Med 1996; 240: 85-92.
• 12 Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: The Tasman Study. N Engl J Med 1996; 334: 682-7.
• 13 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 14 The Columbus Investigators Low-molecular-weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med 1997; 337: 657-62.
• 15 Kirchmaier CM, Wolf H, Schäfer H. et al. Efficacy of a low-molecular-weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Int Angiol 1998; 17: 135-45.
• 16 Breddin HK, Hach-Wunderle V, Nakov R. et al. Effects of two low-molecular-weight heparin regimens on thrombus regression and recurrent venous thromboembolism in the treatment of acute deep vein thrombosis. N Engl J Med 2001; 344: 626-31.
• 17 Kakkar VV, Hoppenstead D, Fareed J. et al. Randomized trial of different regimens of heparin and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99: 1965-70.
• 18 Marder VJ, Soulen RL, Atichartakarn V. et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-29.
• 19 Kamphuisen PW, Eikenboom JC, Vos HL. et al. Increased levels if factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 2000; 4: 703-31.
• 20 Koster T, Rosendaal FR, Reitsma PH. et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DANN polymorphisms – the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
• 21 Ginsberg JS, Brill-Edwards P, Panju A. et al. Pre-operative plasma levels of thrombinantithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Thromb Haemost 1995; 74: 602-5.
• 22 Corradi A, Lazzaro F, Cofrancesco E. et al. Preoperative plasma levels of prothrombin fragment 1 + 2 correlate with the risk of venous thrombosis after elective hip replacement. Acta Orthop Belg 1999; 65: 39-43.
• 23 Peetz D, Hafner G, Hansen M. et al. Dose-adjusted thrombosis prophylaxis in trauma surgery according to levels of D-dimer. Thromb Res 2000; 98: 473-83.
• 24 The DVTENOX Study Group Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-14.
• 25 Speiser W, Mallek R, Koppensteiner R. et al. D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness. Thromb Haemost 1990; 64: 196-201.
• 26 Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 1997; 86: 349-54.
• 27 Estivals M., Pelzer H, Sie P. et al. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-4.
• 28 Mesters RM, Mikoteit T, Schiller M. et al. Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: a prospective study in acute venous thrombosis. Blood Coag Fibrinolysis 1995; 7: 665-7.